Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
CMS proposes to codify the Medicare Drug Price Negotiation Program, which will directly affect pricing and reimbursement for certain high-cost drugs, including some controlled substances. Pharmacies must prepare for potential changes in drug pricing and reporting requirements.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies that dispense Medicare Part D drugs, especially those that may be selected for negotiation. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends 60 days after publication (around August 15, 2026). Final rule expected within 1-2 years.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The proposed rule establishes the framework for Medicare to negotiate prices for certain high-expenditure drugs, which could include controlled substances. It also introduces new reporting and compliance requirements for manufacturers and potentially for pharmacies.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies that dispense Medicare Part D drugs, especially those that may be selected for negotiation.
What you must do
Monitor the rulemaking process and assess which drugs in your inventory may be subject to negotiation. Prepare for potential changes in reimbursement and reporting obligations.
Deadline
Comment period ends 60 days after publication (around August 15, 2026). Final rule expected within 1-2 years.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order